345 Park Avenue South
3rd Floor
New York, NY 10010
United States
646 844 0337
https://www.protaratx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 26
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Mr. Jesse Shefferman | CEO, President & Director | 1.02M | 無 | 1972 |
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder, Senior VP & Chief Scientific Operations Officer | 694.16k | 無 | 1981 |
Mr. Patrick Fabbio M.B.A. | Chief Financial Officer | 696.62k | 無 | 1968 |
Ms. Hannah Fry | VP, Principal Accounting Officer & Controller | 無 | 無 | 1991 |
Ms. Justine O'Malley | Senior Vice President of Investor Relations & Corporate Affairs | 無 | 無 | 無 |
Ms. Mary J. Grendell | General Counsel & Corporate Secretary | 無 | 無 | 無 |
Dr. Jathin Bandari M.D. | Executive Officer | 687.86k | 無 | 1988 |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
截至 無 止,Protara Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。